MX335989B - Compuesto adecuado para el tratamiento de sinucleopatias. - Google Patents
Compuesto adecuado para el tratamiento de sinucleopatias.Info
- Publication number
- MX335989B MX335989B MX2012006740A MX2012006740A MX335989B MX 335989 B MX335989 B MX 335989B MX 2012006740 A MX2012006740 A MX 2012006740A MX 2012006740 A MX2012006740 A MX 2012006740A MX 335989 B MX335989 B MX 335989B
- Authority
- MX
- Mexico
- Prior art keywords
- substituted
- homocyclic
- carbon atoms
- group
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000002723 alicyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28708209P | 2009-12-16 | 2009-12-16 | |
| PCT/US2010/060862 WO2011084642A1 (en) | 2009-12-16 | 2010-12-16 | Compound suitable for the treatment of synucleopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012006740A MX2012006740A (es) | 2012-09-07 |
| MX335989B true MX335989B (es) | 2016-01-07 |
Family
ID=43629477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012006740A MX335989B (es) | 2009-12-16 | 2010-12-16 | Compuesto adecuado para el tratamiento de sinucleopatias. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8846682B2 (OSRAM) |
| EP (1) | EP2513090A1 (OSRAM) |
| JP (2) | JP5922031B2 (OSRAM) |
| KR (1) | KR20120112548A (OSRAM) |
| CN (1) | CN102725284A (OSRAM) |
| AU (1) | AU2010339841B2 (OSRAM) |
| BR (1) | BR112012014807A2 (OSRAM) |
| CA (1) | CA2784744A1 (OSRAM) |
| MX (1) | MX335989B (OSRAM) |
| NZ (1) | NZ600449A (OSRAM) |
| RU (1) | RU2012129882A (OSRAM) |
| WO (1) | WO2011084642A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104363903A (zh) * | 2012-03-28 | 2015-02-18 | 神经孔疗法股份有限公司 | 用作蛋白聚集抑制剂的苯基脲和苯基氨基甲酸盐/酯衍生物 |
| EP2872143B1 (en) * | 2012-07-16 | 2017-12-13 | Neuropore Therapies, Inc. | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation |
| WO2014179303A1 (en) * | 2013-04-29 | 2014-11-06 | The General Hospital Corporation | Amyloid precursor protein mrna blockers for treating down syndrome and alzheimer's disease |
| TR201809440T4 (tr) | 2014-01-29 | 2018-07-23 | Ucb Biopharma Sprl | Protein agregasyonunun inhibitörleri olarak heteroaril amidler. |
| CN104530013B (zh) * | 2014-12-04 | 2016-06-29 | 中国农业大学 | 基于吲哚环的吡唑酰胺类化合物作为农用杀菌剂的用途 |
| ES2885049T3 (es) * | 2015-07-29 | 2021-12-13 | UCB Biopharma SRL | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
| EA201991753A1 (ru) | 2017-01-26 | 2020-01-14 | Юсб Байофарма Спрл | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков |
| KR20190111080A (ko) * | 2017-01-26 | 2019-10-01 | 유씨비 바이오파마 에스피알엘 | 단백질 응집의 조절제로서의 비스-헤테로아릴 유도체 |
| ES2884145T3 (es) * | 2017-01-26 | 2021-12-10 | UCB Biopharma SRL | Derivados bicíclicos de bis-heteroarilo como moduladores de la agregación de proteínas |
| CN110650955B (zh) | 2017-05-11 | 2023-07-25 | 瑞敏德股份有限公司 | 用于治疗癫痫、神经变性病症和其他cns病症的化合物 |
| EP3634407A1 (en) | 2017-05-11 | 2020-04-15 | Remynd N.V. | Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders |
| WO2023125376A1 (zh) * | 2021-12-27 | 2023-07-06 | 上海京新生物医药有限公司 | 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物 |
| TW202412787A (zh) | 2022-07-29 | 2024-04-01 | 日商住友製藥股份有限公司 | 2(1h)-吡啶亞胺衍生物 |
| TW202415651A (zh) | 2022-07-29 | 2024-04-16 | 日商住友製藥股份有限公司 | 含氮飽和雜環衍生物 |
| WO2024102758A2 (en) * | 2022-11-08 | 2024-05-16 | The General Hospital Corporation | N-(n-aminoalkyl)phenanthridiunium series of chloride-sensitive fluorophores and methods of use thereof |
| WO2025002040A1 (zh) * | 2023-06-25 | 2025-01-02 | 上海京新生物医药有限公司 | 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591695A (en) * | 1995-02-08 | 1997-01-07 | American Cyanamid Co. | Herbicidal [1,3,4]oxadiazoles and thiadiazoles |
| EP0726263A3 (en) * | 1995-02-08 | 1996-10-09 | American Cyanamid Co | Herbicides (1,3,4) oxadiazoles and thiadiazoles |
| JP2001505585A (ja) * | 1996-12-16 | 2001-04-24 | 藤沢薬品工業株式会社 | 新規アミド化合物およびそれらの一酸化窒素シンターゼ阻害剤としての用途 |
| US6096688A (en) * | 1996-12-27 | 2000-08-01 | American Cyanamid Company | Oxazole carboxamide herbicides |
| JP2007519753A (ja) * | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| NZ588431A (en) * | 2004-09-17 | 2012-02-24 | Whitehead Biomedical Inst | Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| KR101394245B1 (ko) * | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| US8541406B2 (en) * | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
| EP2007373A4 (en) * | 2006-03-29 | 2012-12-19 | Foldrx Pharmaceuticals Inc | INHIBITION OF ALPHA SYNUCLEINE TOXICITY |
| EP2276726A1 (en) * | 2008-04-18 | 2011-01-26 | University of Connecticut | Compounds for lysosomal modulation and methods of use |
| GB0910003D0 (en) * | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
-
2010
- 2010-12-16 WO PCT/US2010/060862 patent/WO2011084642A1/en not_active Ceased
- 2010-12-16 CA CA2784744A patent/CA2784744A1/en not_active Abandoned
- 2010-12-16 US US13/516,543 patent/US8846682B2/en active Active
- 2010-12-16 JP JP2012544854A patent/JP5922031B2/ja not_active Expired - Fee Related
- 2010-12-16 BR BR112012014807A patent/BR112012014807A2/pt not_active IP Right Cessation
- 2010-12-16 AU AU2010339841A patent/AU2010339841B2/en not_active Ceased
- 2010-12-16 EP EP10805668A patent/EP2513090A1/en not_active Withdrawn
- 2010-12-16 NZ NZ600449A patent/NZ600449A/en not_active IP Right Cessation
- 2010-12-16 RU RU2012129882/04A patent/RU2012129882A/ru not_active Application Discontinuation
- 2010-12-16 CN CN2010800568024A patent/CN102725284A/zh active Pending
- 2010-12-16 MX MX2012006740A patent/MX335989B/es unknown
- 2010-12-16 KR KR1020127018232A patent/KR20120112548A/ko not_active Ceased
-
2014
- 2014-08-21 US US14/465,773 patent/US20140364610A1/en not_active Abandoned
-
2015
- 2015-11-06 JP JP2015218140A patent/JP2016074679A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012014807A2 (pt) | 2017-06-27 |
| US20140364610A1 (en) | 2014-12-11 |
| AU2010339841B2 (en) | 2014-09-25 |
| JP5922031B2 (ja) | 2016-05-24 |
| MX2012006740A (es) | 2012-09-07 |
| EP2513090A1 (en) | 2012-10-24 |
| KR20120112548A (ko) | 2012-10-11 |
| JP2013514980A (ja) | 2013-05-02 |
| US8846682B2 (en) | 2014-09-30 |
| CA2784744A1 (en) | 2011-07-14 |
| US20130035342A1 (en) | 2013-02-07 |
| RU2012129882A (ru) | 2014-01-27 |
| AU2010339841A1 (en) | 2012-07-05 |
| NZ600449A (en) | 2014-10-31 |
| WO2011084642A1 (en) | 2011-07-14 |
| JP2016074679A (ja) | 2016-05-12 |
| CN102725284A (zh) | 2012-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX335989B (es) | Compuesto adecuado para el tratamiento de sinucleopatias. | |
| MX2009005449A (es) | Compuesto heteromonociclico y uso del mismo. | |
| MX2009010024A (es) | Nuevo compuesto de adenina. | |
| MX2010008818A (es) | Derivado de bicicloamina. | |
| MX2009012418A (es) | Derivados de quinazolin-oxima como inhibidores de hsp90. | |
| WO2008114819A1 (ja) | 新規アデニン化合物 | |
| MY161094A (en) | Anti-tumor effect potentiator | |
| MX2012015023A (es) | Derivado novedoso de nicotinamida o sal del mismo. | |
| WO2007122634A3 (en) | Pyrimidinediones as tyrosine kinase inhibitors | |
| NZ608314A (en) | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | |
| TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| MY149180A (en) | Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| MX2011012108A (es) | Sal de clorhidrato de ((1s, 2s, 4r)-4-{4-[(1s)-2, 3-dihidro-1h-inden-1-ilamino]-7h-pirrolo [2, 3-d]pirimidin-7-il}-2 -hidroxiciclopentil)metilsulfamato. | |
| MY167396A (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament | |
| DOP2005000091A (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il) amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico | |
| MY161992A (en) | Novel tetrahydroisoquinoline derivative | |
| IN2012DN03343A (OSRAM) | ||
| IL201795A0 (en) | Stereoisomers propofol therapeutic compounds | |
| WO2009096667A3 (ko) | 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물 | |
| MX342824B (es) | Nuevos compuestos de triazol iii. | |
| EP2604261A3 (en) | SCCA-1 production inhibitor having a carboxamide derivative and/or a salt thereof as an active ingredient | |
| MX2009006243A (es) | Potenciadores del receptor ampa. |